Stock Ideas 
News Letter Reviews Phase 1 Investor Reviews
News Letter Reviews Phase 1 Investor Reviews 
Market Watch
| After the Dow reached a new high on July 17 of over 14,000, the market has quickly turned bearish. Well, if you’re waiting to see how things shake out , then take a look at a few picks that aren’t dependent on the volatile market. | |
| More... |
Most Popular
Login Form
| Phase 1 Investor Reviews |
| Thursday, 05 February 2009 | |||||||||||
|
In short, we only publish Rob's research for a very small audience: folks who have the resources to afford it... cash in on it... and might want to stomach the often bumpy ride of biotech – which most people try to avoid. And that's why we're limiting access to Rob's new Research Report (March 30) to our most expensive and sophisticated advisory service: Phase 1 Investor. To my knowledge – there's no other investment research service in the world that compares to Phase 1 Investor. It costs more to produce than any other advisory at S&A Research... not just in terms of money, but in sheer time alone. To keep up with modern biotech, every month, Rob logs hundreds of air miles, to attend meetings for The American Society of Hematology... The American Society of Clinical Oncology... The Drug Information Association... and many other major meetings of the world's top medical specialists. In other words: Phase 1 Investor is where we publish our most rigorous research. In fact, for many months in the beginning... he didn't allow us to advertise Phase 1 Investor at all. Unless you knew about it, there was no real way to get in. When you join Phase 1 Investor... you'll receive instant access to the transcript along with Rob's full new report: March 30: Biotech's Last Great Blockbuster. As you can see – we do everything we can to make sure the recommendations in Phase 1 Investor are among the best-performing research we publish. And that's why Phase 1 Investor is our most expensive research service. That said, I believe Phase 1 Investor is actually also the best bargain of anything we publish – considering the amount of time... money... and effort that goes into each new recommendation.
The cost for one full year of Phase 1 Investor is $5,000. But there is some good news. For reasons I'll explain shortly – for a limited time only, you can get Phase 1 Investor for almost 50% off the standard price. As I said earlier, that's why we publish Phase 1 Investor: to focus on the kinds of opportunities we simply can't recommend to a mainstream audience. Sign up right now for a trial subscription to Rob Fannon's Phase 1 Investor. You'll have immediate access to Rob's full new report outlining the opportunity I've been telling you about: March 30: Biotech's Last Great Blockbuster. Then, take the next 3 months to decide if Phase 1 Investor is right for you. P.S. Remember – your chance to save ALMOST 50% on a full year of Phase 1 Investor will end shortly. After that... this offer expires.
|
|||||||||||
Reviews (3)
| < Prev | Next > |
|---|
